Novacea, Inc. and Schering-Plough have entered into an exclusive worldwide license agreement for the development and commercialization of Asentar, a novel, proprietary, high-dose oral formulation of calcitriol, a potent hormone that exerts its effects through the vitamin D receptor (VDR). Novacea is currently conducting a large international Phase IIII trial (ASCENT-2) evaluating Asentar in 900 patients with androgen-independent prostate cancer (AIPC). Novacea will receive an upfront payment...